Conceptus — Q4 2010 Earnings Presentation
38 slides from Conceptus's earnings presentation, Feb 24, 2011
Slide 1: Quarterly Results Fourth Quarter 2010
Conceptus Inc. Quarterly Results Fourth Quarter 2010 Exhibit 99.2 February 24, 2011
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements, the accuracy of which is subject to risks and uncertainties. These forward-looking statements include discussions regarding: projected net sales and earn
Slide 3: 2010 Highlights
2010 Highlights Mark Sieczkarek President and Chief Executive Officer
Slide 4: Key Challenges…
Key Challenges… Macro-economic pressures = fewer OB/GYN office visits and elective procedures Growth moderated in U.S. transcervical sterilization market Competitor trialing reduced physician metric growth
Slide 5: …Drove Strategic Initiatives
…Drove Strategic Initiatives Expanded sales force coverage by 50% to minimize competitive impact Provided GYNs value-add services to facilitate Essure ® adoption and utilization Leveraged in-office channel strength: promote GYNECARE THERMACHOICE ®(1) (1) Global endometrial ablation (GEA) product man
Slide 6: In-Office Channel Strength
In-Office Channel Strength Core competency: have successfully developed physician office as the preferred site-of-service for Essure Office-based procedures as % of total volume 70% in Q4’10
Slide 7: Challenge: Reduced Office Visits
Challenge: Reduced Office Visits (1) IMS Data provided by Credit Suisse Healthcare Team Monthly Y/Y Change: Domestic OB/GYN office visits (1) 2010: Average Y/Y decrease = -14% Macro-economic trends contributed to the Y/Y decrease in domestic OB/GYN office visits in 2010
Slide 8: Challenge: Moderating Growth
Challenge: Moderating Growth In $ millions Q3 09 Q4 09 Q1 10 Q2 10 (1) Q3 10 Q4 10 U.S. hysteroscopic sterilization market U.S. Essure Sales $28.0 $28.8 $25.4 $28.0 $27.3 $28.6 Competitor’s Estimated Sales (2) $0.6 $1.5 $2.1 $3.8 $5.2 $5.3 Transcervical Sterilization Market $28.6 $30.3 $27.5 $31.8 $
Slide 9: 2010 Accomplishments
2010 Accomplishments Expanded field sales coverage Achieved 1-3 year account agreements Improved physician metric growth in Q3 and Q4 Provided physicians innovative training and marketing Secured new strategic opportunity to promote GYNECARE THERMACHOICE® to physician offices Gained state Medicaid w
Slide 10: Expanded Field Sales Coverage
We are one of the industry’s largest medical device sales teams dedicated to OB/GYN physicians Expanded Field Sales Coverage Expanded sales coverage and increased sales territories to better align resources: sales personnel in the field, with in direct sales Focus on competitive defense, physician m
Slide 11: Competitor Market Share Flattened
In $ millions Q3 09 Q4 09 Q1 10 Q2 10 (1) Q3 10 Q4 10 Competitor Market Share Flattened U.S. Essure Sales $28.0 $28.8 $25.4 $28.0 $27.3 $28.6 Competitor’s Estimated Sales (2) $0.6 $1.5 $2.1 $3.8 $5.2 $5.3 Transcervical Sterilization Market $28.6 $30.3 $27.5 $31.8 $32.5 $33.9 Competitor’s Share 2.1%
Slide 12: Status of Competitive Trialing
Status of Competitive Trialing 1,000 accounts have trialed to date out of 1,500 to 2,000 accounts anticipated to trial Pace has slowed: The number of accounts entering trialing and the number of competitor cases has decelerated in recent months Trialing expected to last 12 to 15 months at a rate of
Slide 13: Physician Metric Growth Improved
Physician Metric Growth Improved Q4’10 Q3’10 Q2’10 Q1’09 Q4’09 Current Period Activity: Physicians entering preceptorship Physicians becoming certified Physicians transitioning to office Physician Base: 12,530 12,117 11,742 11,355 10,932 U.S. physician metrics grew in Q4’10
Slide 14: Provided Innovative Physician Services
Provided Innovative Physician Services VirtaMed’s state-of-the-art EssureSim (TM) simulates the Essure hysteroscopic procedure Value-add services drive Essure adoption and utilization Assist individual physicians in building their Essure practice Educate physician office support personnel on Essure’
Slide 15: Secured Strategic Partnership
Secured Strategic Partnership Essure and GYNECARE THERMACHOICE® are compatible in- office procedures Patients are strongly advised not to get pregnant if they have a GEA procedure, making Essure medically necessary An estimated 50% of GEA patients do not have permanent birth control We began promoti
Slide 16: GEA In-Office Opportunity
GEA In-Office Opportunity 15% 18% GYNECARE THERMACHOICE procedures by site-of-service In-office procedures Hospital procedures $400 million annual GEA market in U.S. Based on company estimates All GEA brands
Slide 17: Partnership Synergies
Partnership Synergies Benefits for Ethicon: Increase in-office procedures – Establish larger in-office market share by leveraging Conceptus in-office channel strength Benefits for Conceptus: Increase utilization of Essure – Accounts perform to GEA procedures per month – Opportunity is 50% of patient
Slide 18: Gained Additional Medicaid Wins
Gained Additional Medicaid Wins 33 states provided Essure Medicaid fee - for - service office reimbursement of at least $1,700 as of 12/31/10 9 states improved Medicaid reimbursement in 2010: Colorado, Connecticut, Illinois, Indiana, North Dakota, Ohio, Texas, Utah and Wisconsin AK WA OR CA NV ID MT
Slide 19: Fourth Quarter 2010 Financials
Fourth Quarter 2010 Financials Greg Lichtwardt Executive Vice President, Operations and Chief Financial Officer
Slide 20: Q4'10 Snapshot
Q4’10 Snapshot Net Sales ($mm) Gross Margin (%) Diluted GAAP EPS Operating Margin (%) EBITDA (1) ($mm) Q4’09 Q4’10 Q4’09 Q4’10 Q4’09 Q4’10 Q4’09 Q4’10 Q4’09 Q4’10 $37.0 82.2% 81.9% $36.6 22.2% 16.8% $0.21 $2.66 (2) $11.9 (1) Earnings before interest, taxes, depreciation, amortization and equity- bas
Slide 21: Worldwide Sales
Worldwide Sales $28.8 (78%) $28.6 (78%) 20.9 (66%) 11.0 (34%) 21.0 (65%) 11.4 (35%) $8.0 (22%) $8.2 (22%) Q4’10 Net Sales (in million $) Q4’10 Units (in thousands) : $37.0 Q4’09 Q4’10 $36.6 31.9 Q4’09 Q4’10 32.4 Domestic International
Slide 22: Q4'10 Results
Q4’10 Q4’09 Y/Y Change Q3’10 Q/Q Change Q4’10 Results Net Sales $36.6 $37.0 (1.1 %) $33.9 8.0% Gross Profit Margin 81.9% 82.2% nm 80.6% nm Operating Expenses $23.8 $22.2 7.2% $24.6 (3.3%) EBITDA (1) $10.1 $11.9 (15.1%) $6.6 53.0% Other Income / (Expense) ($1.6) ($1.6) nm ($1.6) nm Tax Provision (ben
Slide 23: Q4'10 EBITDA
Q4’10 EBITDA EBITDA $10.1 Amortization of intangibles Equity-based compensation $1.3 $0.8 $1.8 $6.2 Operating income See reconciliation in appendix Depreciation expense $ millions
Slide 24: 2010 EBITDA
2010 EBITDA EBITDA $24.8 Amortization of intangibles Equity-based compensation $4.7 $3.3 $7.3 $9.5 Operating income See reconciliation in appendix Depreciation expense $ millions
Slide 25: Balance Sheet
Balance Sheet Cash & cash equivalents Investments and put option (1) A/R, inventories & other current assets PP&E Intangible and other assets Goodwill Deferred tax asset Total assets ASSETS 18.4 72.5 29.7 10.1 25.2 16.0 78.8 250.7 61.7 43.5 25.7 9.8 29.1 17.3 0.0 187.1 12/31/10 A/P & other accrued S
Slide 26: Guidance
Guidance FY’10A FY’11E Net Sales $135mm to $150mm $140.7mm Gross Profit Margin 82.0% to 82.5% 80.9% Operating Expenses $102mm to $105mm $104.3mm EBITDA (1) $24.7mm to $34.7mm $24.8mm (1) See appendix
Slide 27: 2011: Vision, Strategy and Growth Drivers
2011: Vision, Strategy and Growth Drivers Mark Sieczkarek President and Chief Executive Officer
Slide 28: Who We Are
Who We Are Mission: Revolutionizing women’s healthcare with innovative solutions Vision: Make Essure standard of care in permanent birth control market
Slide 29: Our Approach in 2011
Our Approach in 2011 1. Successfully navigate the “new normal” economy – Assume continued high unemployment – Assume high deductible insurance plans remain popular and patient utilization rates remain low, especially for non-urgent procedures like Essure 2. Minimize impact of competition – Continue
Slide 30: Our Approach in 2011
Our Approach in 2011 3. Accelerate Essure sales by leveraging GEA in- office synergy 4. Drive market awareness and adoption of Essure through cost effective direct-to-consumer marketing initiatives – Online, digital, viral – Patient education
Slide 31: Our Approach in 2011
Our Approach in 2011 5. Expand our presence in international markets – France: Age 40+ market – China and India – WomanCare Global to distribute Essure in Ghana, Kenya, Mexico, Puerto Rico, and Turkey 6. Washington DC focus and reimbursement issues – Inclusion of contraception in the Preventative Se
Slide 32: Our Approach in 2011
Our Approach in 2011 7. Create a pipeline of women’s health products and services that accelerate adoption of Essure – Therapeutic – Prefer office site-of-service 8. Product enhancements – Begin clinical trials of fifth generation Essure – Seek FDA approval of transvaginal ultrasound (TVU) for Essur
Slide 33: Growth Drivers
Growth Drivers Increasing sales force productivity Competitive trialing slowdown Increase utilization of Essure through the promotion of ThermaChoice in U.S. physician offices Leverage marketing synergies between physician and consumer audiences Continue to build relationships with OB/GYN communitie
Slide 34: Conceptus' Inc.
Conceptus' Inc.
Slide 35: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures The Company has supplemented its GAAP operating income with a non-GAAP measure of earnings before interest, taxes, depreciation, amortization and equity-based compensation (“EBITDA”). Management believes that this non- GAAP financial measure provides useful supplem
Slide 36: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 2010 2009 2010 2009 Operating income, as reported 6,148 $ 8,195 $ 9,549 $ 14,643 $ Adjustments to net income: Amortization of intangibles (a) 3,254 1,387 Equity-based compensation (b) 1,833 1,726 7,246 6,282 Depreciation expense (c) 1,283 1,124 4,701 4,101 Adjustments
Slide 37: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation From To Operating Income Guidance 8,592 $ 18,592 $ Estimated Non-GAAP Guidance Amortization of intangibles (a) 3,261 $ 3,261 $ Equity-based compensation (b) 7,571 $ 7,571 $ Depreciation expense (c) 5,250 $ 5,250 $ Adjustments to operating income 16,082 $ 16,082 $ Non-
Slide 38: Thank You
Thank You CC-2642 24FEB11F